Company of the week: Poxel SA: Navigating Judicial Reorganization While Clinical Assets Retain Promise
Poxel SA, a French biopharmaceutical company that successfully developed and commercialized the first-in-class diabetes drug TWYMEEG® in Japan, filed for
Fund of the week: OrbiMed Royalty & Credit Opportunities
Executive Summary
OrbiMed's Royalty & Credit Opportunities strategy has emerged as a prominent non-dilutive financing platform in the
Venture Debt in Biotech & Pharma: A 2025 Comprehensive Analysis
Venture Debt in Biotech & Pharma: A 2025 Deep Dive
Introduction: The Rise of Biotech Venture Debt
Venture debt has
Pharmaceutical Royalty Structures: A Global Technical Analysis
Executive Summary
In the pharmaceutical industry, royalties serve as a fundamental mechanism for sharing value from intellectual property and products.
Lilly’s TuneLab: accelerator, equaliser—or a gilded cage?
Eli Lilly’s latest act of corporate altruism arrived in September 2025 in the form of TuneLab, an artificial intelligence
The weekly term sheet (37)
Pharmaceutical & Biotech Transactions: September 8-14, 2025
Executive Summary
The week of September 8-14, 2025 witnessed 22 verified transactions in
Fractional Biotech Equity: From Experimental Concept to $1.3 Billion Alternative Funding Mechanism
Fractional equity funding for biotech companies - achieved through traditional securities divided into smaller units rather than cryptocurrency - has
Company of the week: Absci Corporation
Absci Corporation (NASDAQ: ABSI) stands at a pivotal crossroads in September 2025, having transitioned from a pure AI drug discovery
Fund of the Week: Neo Kuma Ventures – Europe's Psychedelic Medicine Specialist
Executive Summary
Neo Kuma Ventures, established in December 2020 as Europe's first venture fund dedicated to psychedelic healthcare,
Global Radiopharmaceutical Patent Wars
The radiopharmaceutical industry has erupted into an all-out patent war in 2024-2025, with Novartis at the center of a multi-billion
